Navigation Links
PharmAthene Reports Third Quarter 2013 Financial And Operational Results
Date:11/7/2013

ANNAPOLIS, Md., Nov. 7, 2013 /PRNewswire/ -- 

Recent Highlights

  • On track to commence SparVax® Phase 2 clinical trial
  • Presented new SparVax® anthrax vaccine data at the 2013 Bacillus-ACT International Conference and the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
  • Advanced proposed merger with Theraclone Sciences; filed amended Form S-4 registration statement and set date for special stockholders meeting
  • PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the third quarter ended September 30, 2013.

    "Progress in our next generation SparVax® anthrax vaccine program continued at a steady pace in the third quarter," commented Eric I. Richman, President and Chief Executive Officer.  "PharmAthene scientists presented new analytical and non-clinical animal data for SparVax® at two important medical meetings. The data provided further confirmation of the immunogenicity and efficacy of SparVax® and demonstrated our progress in developing a newer, more robust functional assay for anthrax vaccine development.  We are also pleased to report that we are on track to initiate the planned Phase 2 clinical trial of SparVax®, which we anticipate will begin by the end of the year."

    Mr. Richman continued, "Most importantly, during the third quarter we announced our proposed merger with Theraclone Sciences, a privately-held company with impressive monoclonal antibody (mAb) discovery and development capabilities. Following the completion of the merger, the new company will feature vaccine and human monoclonal antibody expertise with a focus on infectious diseases and oncology and a robust pipeline with four clinical-stage and multip
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
    2. PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
    3. PharmAthene Reports First Quarter 2013 Financial And Operational Results
    4. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
    5. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
    6. Pharmacyclics Reports Third Quarter 2013 Results
    7. CareFusion Reports First Quarter Fiscal 2014 Results
    8. Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2013
    9. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
    10. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    11. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
    (Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
    (Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
    Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
    ...  In a move aimed at bolstering current systems for assessing ... created a new method that combines multiple forms of widely ... which rely on detecting evidence of drug safety issues as ... may be able to identify issues years in advance. ...
    ... Systems, Inc. (NASDAQ: DCTH ) appointed Gregory ... "As a widely respected hepatologist and 2011 ... Gores will contribute a wealth of clinical knowledge on ... Advisory Board," said Eamonn P. Hobbs, CEO & President ...
    Cached Medicine Technology:Taking a Predictive Approach to Identifying Adverse Drug Reactions 2Taking a Predictive Approach to Identifying Adverse Drug Reactions 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4
    (Date:8/30/2014)... Daily Gossip reveals in its review a program ... program, who shows a unique formula to get inside a ... says that the program goes beyond mere attraction and actually ... review indicates that the program was created by dating expert ... techniques to make a man feel emotionally addicted. , Learn ...
    (Date:8/30/2014)... (PRWEB) August 30, 2014 The Plastic ... in New Jersey and even in the U.S. to ... takes inches off of patients’ waists with deep-tissue heating. ... in small sections, Vanquish is more inclusive to target ... Patients lay comfortably under panels about one inch away ...
    (Date:8/30/2014)... 30, 2014 Ticket Down ... Tennis Championship tickets in NYC. This popular ... US-OPEN-2014 for all day session, evening session, courtside seats, ... for this prestigious Grand Slam Tournament. , The 2014 ... , US Open Tennis Championship: Men's/Women's 3rd Round - ...
    (Date:8/30/2014)... a common problem millions of American cope with every day. While ... for some, it can have a crippling impact on social activity ... mood swings and depression. , Those struggling with acne are ... some cases, that can make the problem even worse. Instead of ... quest for clearer skin can now view acne treatment reviews ...
    (Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... incretin mimetic claims continue to move forward in U.S. ... issued by AstraZeneca PLC on July 31, 2014, Byetta ... named in 409 product liability claims that allege the ... documents indicate that many of these claims are pending ...
    Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3
    ... of a dedicated pediatric imaging department (with dedicated pediatric computed ... radiation dose delivered to the patient, according to a study ... American College of Radiology. ... outweigh the potential long-term risk of radiation. To minimize the ...
    ... mammography screening every other year outweigh the potential harms for ... risk of developing breast cancer -- a finding that could ... researchers also found greater harms from screening done with digital ... three national research groups, are published in the May 1 ...
    ... , MONDAY, April 30 (HealthDay News) -- ... to remove the esophagus of patients with esophageal cancer ... compared to traditional open surgery, a new study finds. ... this less-invasive procedure have much shorter hospital stays and ...
    ... way deaf and hard-of-hearing students learn are multifaceted: ... skills in both American Sign Language and spoken ... learning strategies. Further understanding of these unique ... particularly in science, technology, engineering and mathematics, the ...
    ... born every hour addicted to opiate drugs in the United ... In the research published April 30 in the ... that diagnosis of neonatal abstinence syndrome, a drug withdrawal syndrome ... 2009, the estimated number of newborns with the syndrome was ...
    ... , MONDAY, April 30 (HealthDay News) -- Just ... healthy, a veterinarian says. "Dogs should get exercise at ... each session for small dogs and 30 to 40 minutes ... at the Veterinary Medical Teaching Hospital at Kansas State University ...
    Cached Medicine News:Health News:Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose 2Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 2Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 3Health News:Less-Invasive Surgery for Esophageal Cancer Might Be Safer 2Health News:Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students 2Health News:About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows 2Health News:About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows 3Health News:Exercise Twice a Day Vital for Your Dog's Health, Expert Says 2
    MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
    Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
    ... Monoclonal antibody method for HbA1c provides outstanding ... 99% agreement with the HPLC method(1) , ... a CV of 2.6%* means your results ... (NGSP) certified method, as recommended by the ...
    The sole coagulation analyzer in the world that uses a unique dry reagent card....
    Medicine Products: